melanocortin receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
| Property | Value | Notes |
|---|---|---|
| Primary receptor targets | MC4R and MC1R | Agonist activity; MC3R and MC5R weaker |
| Route studied in trials | Subcutaneous injection | Intranasal form was not approved |
| Elimination half-life | Approximately 2–3 hours | Short relative to the dosing interval |
| Common analytical method | Liquid chromatography–tandem mass spectrometry | Used for peptide quantification in plasma |
| Reported adverse events | Nausea, flushing, headache | Transient blood pressure rise also noted |
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Dose—From 10 to 30 drops for adults, according to the strength of the patient, or severity of the pain. Thirty drops of this laudanum will be equal to one grain of opium. And this is a much better way to prepare it than putting the opium into alcohol, or any other spirits alone, for in that case much of the opium does not dissolve." The remaining three formulas are copied from an 1890 publication of the day:
== Mechanism == Antivenoms act by binding to and neutralizing venoms. The principle of antivenom is based on that of vaccines, developed by Edward Jenner; however, instead of inducing immunity in the person directly, it is induced in a host animal and the hyperimmunized serum is transfused into the person. The host animals may include horses, donkeys, goats, sheep, rabbits, chickens, llamas, and camels. In addition, opossums are being studied for antivenom production, as unique opossum blood proteins such as lethal toxin neutralizing factor can neutralize snake venoms. Antivenoms for medical use are often preserved as freeze-dried ampoules, but some are available only in liquid form and must be kept refrigerated. They are not immediately inactivated by heat, however, so a minor gap in the cold chain is not disastrous.
Controversial statements with anti-Peruvian overtones in some political sectors of the country are also mentioned, such as those of Justicialist senator Miguel Ángel Pichetto, when mentioning that Peru transferred its security problems through the migration of its criminals to Argentina, reaching a generalization that the main towns in the country were taken by Peruvians and that Argentina incorporates all this hangover, the controversy became even greater when even the Government of Argentina agreed with those statements. He also went so far as to affirm that Argentina has become ill for giving a pardon to a deported Peruvian (for having sold drugs) and that second chances should not be given, as well as accusing Peruvians of being responsible for the crimes in the slums. and the drug trade among young people, although clarifying that he did not say it for all Peruvians. Later there was concern, in 2019, of Peruvian diplomats about Pichetto's nomination for the Argentine vice presidency, due to having anti-Peruvian sentiments that could affect bilateral relations between the two countries. Later, in 2020, he declared that the Buenos Aires suburbs are the social adjustment of Peru, Bolivia, Paraguay and Venezuela. It is usually assumed that this xenophobia of Argentines towards Peruvians and other nationalities they have been scapegoats many times for a political discourse that prefers not to assume its own responsibility.
== History == The Human Genetics Society of Australasia was founded subsequent to the growth in the field of genetics that occurred during the mid-twentieth century. During this time, the role that genetics plays in human health and disease became increasingly recognized. Genetic diagnostic techniques (in particular, in cytogenetics) were progressing rapidly. This coincided with the appreciation by medical specialists that genetic disorders, especially inborn errors of metabolism and birth defects, were of clinical interest. In 1976, a meeting in clinical genetics was held as part of the celebrations of the Centenary Year of the Adelaide Children's Hospital. The meeting involved several high-profile international speakers, most of the senior medical practitioners with an interest in heritable disease working in Australia and New Zealand, and delegates of the annual meeting of local cytogeneticists. The group agreed that a small working group should be charged with setting up a human genetics society for the region. Subsequently, the Human Genetics Society of Australasia was formally incorporated in South Australia in 1977 to serve the Australia and New Zealand region. The original group consisted of 19 Foundation Members, paying just $A10 per annum for membership.
1962 Pittsburgh Award 1963 Election to membership in the National Academy of Sciences 1963 Borden Medal 1963 Chancellors Medal, University of Pittsburgh 1972 Mellon Lecture, University of Pittsburgh 1976 Senior Scientist Award, Alexander Von Humboldt Foundation, Bonn, West Germany 1981 Third Alan E. Pierce Award by the American Peptide Chemists 1983 Japan Society for the Promotion of Sciences Fellowship Award 1987 First Huggins Memorial Award, University of Pittsburgh
Sources: en.wikipedia.org
Treatment can be with oral therapy such as pentoxifylline (an anti-fibrotic phosphodiesterase inhibitor). Pentoxifylline lowers inflammation by blocking transforming growth factor beta 1 (TGF-β1), which interferes with the production of collagen type I. Pain management in the active phase of the disease can be provided by non-steroidal anti-inflammatory drugs (NSAID). One of the main symptoms of active Peyronie's disease is pain with or without erection. Pain is often distressing to patients and may compromise sexual function. Pain level should be periodically checked to measure treatment efficacy. Not recommended oral therapies include Acetyl-L-carnitine and vitamin E .
=== Depression === Escitalopram is among the most effective and well-tolerated antidepressants for the short-term treatment of major depressive disorder in adults. It also seems to be the safest one to give to children and adolescents. Controversy existed regarding the effectiveness of escitalopram compared with its predecessor, citalopram. The importance of this issue followed from the greater cost of escitalopram relative to the generic mixture of isomers of citalopram, prior to the expiration of the escitalopram patent in 2012, which led to charges of evergreening. Accordingly, this issue has been examined in at least 10 different systematic reviews and meta analyses. As of 2012, reviews had concluded (with caveats in some cases) that escitalopram is modestly superior to citalopram in efficacy and tolerability.
Brazil is a developing country with an upper-middle income mixed market economy that is rich in natural resources. It has the largest national economy in Latin America, the tenth largest economy in the world by nominal GDP, and the eighth largest by PPP. After rapid growth in preceding decades, Brazil entered a recession in 2014 amid a political corruption scandal and nationwide protests; in 2024, the economy began showing consistent significant growth. Brazil has a labor force of roughly 100 million, which is the world's fifth largest. Its foreign exchange reserves are the tenth-highest in the world. The B3 in São Paulo is the largest stock exchange of Latin America by market capitalization. Roughly one-fifth of Brazilians live in poverty: about 3.8% of the total population lives at $3.00 a day, while about 23% live at $8.30 a day. Brazil's economy suffers from endemic corruption and high income inequality. The Brazilian real is the national currency. Brazil's diversified economy includes agriculture, industry and a wide range of services. The large service sector accounts for about 72.7% of total GDP, followed by the industrial sector (20.7%), while the agriculture sector is by far the smallest, making up 6.6% of total GDP. Brazil is one of the largest producers of various agricultural commodities, and also has a large cooperative sector that provides 50% of the food in the country.
Researchers surveyed 1,520 children, ages 9–10, with a four-year follow up and discovered a positive correlation between obesity and low self-esteem in the four-year follow up. They also discovered that decreased self-esteem led to 19% of obese children feeling sad, 48% of them feeling bored, and 21% of them feeling nervous. In comparison, 8% of normal weight children felt sad, 42% of them felt bored, and 12% of them felt nervous. Stress can influence a child's eating habits. Researchers tested the stress inventory of 28 college females and discovered that those who were binge eating had a mean of 29.65 points on the perceived stress scale, compared to the control group who had a mean of 15.19 points. This evidence may demonstrate a link between eating and stress. Feelings of depression can cause a child to overeat. Researchers provided an in-home interview to 9,374 adolescents, in grades seven through 12 and discovered that there was not a direct correlation with children eating in response to depression. Of all the obese adolescents, 8.2% had said to be depressed, compared to 8.9% of the non-obese adolescents who said they were depressed. Antidepressants, however, seem to have very little influence on childhood obesity.
Sources: en.wikipedia.org
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.
Nausea, flushing, headache, and transient blood pressure elevation are the most frequently reported events. These typically appear shortly after dosing and are usually described as mild to moderate in severity. Safety data covering long periods of continuous use remain limited.
A short half-life means the compound clears from circulation within hours, so any effect is tied closely to dosing time. Accumulation between doses is therefore unlikely under the studied schedule. The practical consequence is that timing of administration shapes what observers record.
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.